Company news: Valeant and Regeneron

Share this article:
Weeks after bringing Medicis into the fold, Valeant is once again expanding its portfolio. The Canadian company announced Monday it scooped up rights to QLT's drug Visudyne for $112.5 million. The drug is used to treat leaky blood vessels associated with wet age-related macular degeneration. The company said in a statement that the upfront payment breaks down into $62.5 million for US rights and $50 million for non-US rights, which had respective sales of about $21 million and $14 million last year. The deal also includes an agreement to pay a $5 million contingency fee related to QLT's laser program in the US and a $15 contingency payment for the same program outside of the US.

The FDA has cleared Regeneron's Eylea for an additional use. The injection, which was initially approved for wet age-related macular degeneration, has now been given the all-clear for macular edema following central retinal vein occlusion. The approval was based on data from Phase III Copernicus and Galileo studies which had a goal of patients gaining the ability to see at least 15 letters of Best Corrected Visual Acuity after 24 weeks.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.